Oncotarget

Reviews:

Generation of induced cardiac progenitor cells via somatic reprogramming

Jianyong Xu _, Wei Lian, Lingyun Li and Zhong Huang

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:29442-29457. https://doi.org/10.18632/oncotarget.15272

Metrics: PDF 1238 views  |   HTML 1980 views  |   ?  


Abstract

Jianyong Xu1,2,3, Wei Lian1,2,3, Lingyun Li1,2,3 and Zhong Huang1,2,3

1 Institute of Biological Therapy, Shenzhen University, Shenzhen, China

2 Department of Pathogen Biology and Immunology, Shenzhen University School of Medicine, Shenzhen, China

3 Shenzhen City Shenzhen University Immunodiagnostic Technology Platform, Shenzhen, China

Correspondence to:

Jianyong Xu, email:

Zhong Huang, email:

Keywords: cardiac progenitor cell, CPC, somatic reprogramming, induced CPC

Received: November 30, 2016 Accepted: January 24, 2017 Published: February 10, 2017

Abstract

It has been demonstrated that cardiac progenitor cells (CPCs) represent a more effective cell-based therapy for treatment of myocardial infarction. Unfortunately, their therapeutic application is limited by low yield of cell harvesting, declining quality and quantity during the ageing process, and the need for highly invasive heart biopsy. Therefore, there is an emerging interest in generating CPC-like stem cells from somatic cells via somatic reprogramming. This novel approach would provide an unlimited source of stem cells with cardiac differentiation potential. Here we would firstly discuss the different types of CPC and their importance in stem cell therapy for treatment of myocardial infarction; secondly, the necessity of generating induced CPC from somatic cells via somatic reprogramming; and finally the current progress of somatic reprogramming in cardiac cells, especially induced CPC generation.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15272